

## NEW ACCOUNTING STANDARDS IMPACT IFRS-9, IFRS-15, IFRS-16, IAS-29 & IAS-21

**Mexico City, April 29, 2019 – Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB)** (“Genomma Lab” or “the Company”), one of the leading pharmaceutical and personal care products companies in Mexico with an increasing international presence, today informed that it has published in its webpage a document detailing the adoption of the new accounting standards IFRS-9, IFRS-15 and IFRS-16.

This document, also includes the explanation and impact of the accounting effects (non-cash) derived from the adoption of the hyperinflationary accounting (IAS-29 and IAS-21) on the Company’s financial statements from the Argentina’s operations, since January 1, 2018.

Please click the following link to read the document:

[Non-Cash Accounting Adjustments under IFRS Standards](#)

---

### About Genomma Lab Internacional

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Latin America. Genomma Lab develops, sells and markets a broad range of Premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. The Company has a sound business model through a unique combination of a new product development process, consumer oriented marketing, a broad retail distribution network and a low-cost, highly flexible supply chain operating model. For more information visit: [www.genommalab.com](http://www.genommalab.com)

Genomma Lab’s shares are listed on the Mexican Stock Exchange under the ticker **“LABB” (Bloomberg: LABB:MM)**.

### Note on Forward-Looking Statements

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like “believe,” “anticipate,” “expect,” “envisages,” “will likely result,” or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.